- Trials with a EudraCT protocol (280)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
280 result(s) found for: Intranasal.
Displaying page 2 of 14.
EudraCT Number: 2011-000115-11 | Sponsor Protocol Number: VR1111924 | Start Date*: 2011-04-19 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Ltd | |||||||||||||
Full Title: A randomized, double-blind, placebo controlled, incomplete block, 3 way cross over study in subjects with allergic rhinitis to assess the effect of intranasal repeat doses of SB-705498 when adminis... | |||||||||||||
Medical condition: Allergic rhinitis. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002848-22 | Sponsor Protocol Number: MV-004 | Start Date*: 2020-12-03 | |||||||||||
Sponsor Name:Meissa Vaccines Inc. | |||||||||||||
Full Title: A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Prophylactic Efficacy of MV-012-968 Against Respiratory Syncytial Virus (RSV) Infection in the Virus Challe... | |||||||||||||
Medical condition: Respiratory Syncytial Virus Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003820-22 | Sponsor Protocol Number: 2016-Longterm-OX | Start Date*: 2016-12-22 | |||||||||||
Sponsor Name:Dutch Growth Research Foundation | |||||||||||||
Full Title: Intranasal administration of oxytocin in children with Prader-Willi Syndrome. A randomized, open-label, cross-over trial of different treatment regimens of oxytocin administration. Effects on eatin... | |||||||||||||
Medical condition: Prader-Willi syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Not Authorised) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-008324-33 | Sponsor Protocol Number: 900, version 1.0 | Start Date*: 2009-03-18 |
Sponsor Name:Sanna Vilo | ||
Full Title: Bioavailability of dexmedetomidine after intranasal administration in healthy subjects | ||
Medical condition: healthy volunteers | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: FI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-001665-16 | Sponsor Protocol Number: 1312 | Start Date*: 2013-08-01 |
Sponsor Name:University Hospital Grenoble | ||
Full Title: Intranasal Sufentanyl analgesia Versus Morphine IV in Emergency room. | ||
Medical condition: | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-003307-13 | Sponsor Protocol Number: 07-001 | Start Date*: 2008-01-28 | |||||||||||
Sponsor Name:Jazz Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2a, Open-label, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Intranasal Clonazepam in Adult Subjects with Epileptic Seizures | |||||||||||||
Medical condition: Recurrent Acute Repetitive Seizures (ARS) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001567-37 | Sponsor Protocol Number: KUKIDEX-2 | Start Date*: 2016-11-24 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Efficacy of single dose intranasal dexmedetomidine for conscious sedation in dental practice in dentophobic uncooperative patients with intellectual disability. | ||
Medical condition: dentophobia intellectual disability | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-004463-37 | Sponsor Protocol Number: 140682 | Start Date*: 2016-06-20 |
Sponsor Name:St. Olavs Hospital | ||
Full Title: ACUTE AND LONG-TERM EFFECTS OF INTRANASAL OXYTOCIN IN ALCOHOL WITHDRAWAL AND DEPENDENCE: A PROSPECTIVE RANDOMIZED PARALLEL GROUP PLACEBO-CONTROLLED TRIAL | ||
Medical condition: alcohol withdrawal and craving. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-002282-35 | Sponsor Protocol Number: rh-NGF | Start Date*: 2020-05-13 | |||||||||||
Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE | |||||||||||||
Full Title: Nerve growth factor in pediatric severe traumatic brain injury : translational and clinical studies on a candidate biomarker and therapeutic drug | |||||||||||||
Medical condition: Persistent unresponsive wakefulness syndrome (UWS) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004456-42 | Sponsor Protocol Number: P2021/Anesth/MIDEXMRI | Start Date*: 2022-06-21 |
Sponsor Name:Hôpital Universitaire Des Enfants Reine Fabiola | ||
Full Title: Prospective, randomized, double-blind, double-dummy, active-controlled, phase 3 clinical trial comparing the safety and efficacy of intranasal dexmedetomidine to oral midazolam as premedication for... | ||
Medical condition: pre-school pediatric population undergoing magnetic resonance imaging | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-001288-58 | Sponsor Protocol Number: 40122 | Start Date*: 2012-05-21 | |||||||||||
Sponsor Name:Academic Medical Center | |||||||||||||
Full Title: Boosting oxytocin after trauma: The effects of intranasal oxytocin administration on emotional and motivational brain processes in PTSD | |||||||||||||
Medical condition: Posttraumatic Stress Disorder (PTSD) according to criteria in the DSM-IV | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004005-11 | Sponsor Protocol Number: ESKETINTRD2003 | Start Date*: 2013-12-17 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Double-Blind, Doubly-Randomized, Placebo-Controlled Study of Intranasal Esketamine in an Adaptive Treatment Protocol to Assess Safety and Efficacy in Treatment-Resistant Depression (SYNAPSE) | |||||||||||||
Medical condition: Treatment Resistant Major Depression | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004588-19 | Sponsor Protocol Number: ESKETINTRD3005 | Start Date*: 2015-08-04 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Subjects with Tre... | |||||||||||||
Medical condition: Treatment-resistant Major Depression | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) BE (Completed) ES (Completed) GB (Completed) LT (Completed) FI (Completed) BG (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000298-35 | Sponsor Protocol Number: NL60593.028.17 | Start Date*: 2017-05-01 |
Sponsor Name:Tilburg University | ||
Full Title: Oxytocin, friendship and dealing with emotions | ||
Medical condition: There are no medical conditions or disease under investigation. | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2004-004749-17 | Sponsor Protocol Number: FFR101747 | Start Date*: 2005-03-22 |
Sponsor Name:GlaxoSmithKline Research & Development Ltd | ||
Full Title: A randomized, double-blind, placebo-controlled, 2-week crossover, knemometric assessment of the effect of once daily GW685698X Aqueous Nasal Spray 100 mcg on short term growth in children ages 6 - ... | ||
Medical condition: Seasonal and/or perennial allergic rhinitis | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-004585-22 | Sponsor Protocol Number: ESKETINTRD3002 | Start Date*: 2015-08-10 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult S... | |||||||||||||
Medical condition: Treatment-resistant Major Depression | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PL (Completed) ES (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005420-17 | Sponsor Protocol Number: CC10-200601 | Start Date*: 2007-01-23 |
Sponsor Name:LTB4 Sweden AB | ||
Full Title: A double-blind, randomised, placebo-controlled, crossover, allergen challenge study, evaluating the safety, tolerability and effects of intranasal administration of recombinant human Clara Cell 10 ... | ||
Medical condition: The study is a proof-of-concept study with the objective to investigate whether rhCC10, administered intranasally, can affect the response to an allergen provocation test in subjects with allergic ... | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-005531-99 | Sponsor Protocol Number: NAI003/I | Start Date*: 2006-04-10 |
Sponsor Name:University of Dundee(Research & Innovation Services) | ||
Full Title: A PROOF OF CONCEPT STUDY TO ASSESS THE STEROID SPARING EFFECT OF COMBINED NASAL AND INHALED CORTICOSTEROID IN PATIENTS WITH ASTHMA AND PERSISTENT RHINITIS | ||
Medical condition: Bronchial Asthma | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-005201-31 | Sponsor Protocol Number: INNalox-1 | Start Date*: 2015-03-31 |
Sponsor Name:Karolinska University Hospital | ||
Full Title: Pharmacokinetic profile and pharmacodynamic effects after intranasal naloxone administration in volunteers and pediatric patients. | ||
Medical condition: Sedation after opioid administration Pharmacokinetic profile after naloxone administered intranasally | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18, Adults | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-003273-18 | Sponsor Protocol Number: RC31-15-7837 | Start Date*: 2016-11-14 |
Sponsor Name:University Hospital of Toulouse | ||
Full Title: Effects of intranasal administrations of oxytocin on beahvioural troubles, hyperphagia and social skills in children with Prader-Willi syndrome aged from 3 to 12 years. | ||
Medical condition: Prader-Willi Syndrom | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
